Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) gene rearrangement in advanced non-small cell lung cancer (NSCLC) represent the two oncogenic events with an impact on current clinical practice. EGFR tyrosine kinase inhibitors (TKIs) and crizotinib ar...
Main Authors: | Ourania Romanidou, Lorenza Landi, Federico Cappuzzo, Raffaele Califano |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016631531 |
Similar Items
-
Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
by: Xiaoling Song, et al.
Published: (2021-09-01) -
Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC
by: Recondo, Gonzalo
Published: (2019) -
The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
by: Cosimo Lobello, et al.
Published: (2018-03-01) -
ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
by: Federica Lovisa, et al.
Published: (2015-01-01) -
Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)